Tevogen Bio Inc

7 articles with Tevogen Bio Inc

• Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors

  8/17/2022

  Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, is pleased to announce the appointment of three new members to its Board of Directors.

• Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients

  8/1/2022

  Tevogen Bio, a late stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, today announced that it completed enrollment in the Proof-of-Concept clinical trial of the company’s lead investigational product, TVGN-489, for elderly or high-risk ambulatory COVID-19 patients.

• Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D

  7/7/2022

  Acclaimed oncologist and immunotherapy expert Neal Flomenberg, M.D. joins Tevogen Bio as Chief Scientific Officer (CSO) and Global Head of Research & Development.

• Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

  6/30/2022

  Tevogen Bio announced its new Research and Development Center located in Philadelphia’s historic Wanamaker building to further expand the company’s R&D capability allowing expansion of its precision T cell product pipeline.

• Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board

  6/23/2022

  Tevogen Bio, a late-stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced that its Board of Directors has appointed Kendell R. Sprott, M.D., J.D., to its Corporate Advisory Board.

• Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

  6/7/2022

  Tevogen Bio, a late-stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced it has initiated the fourth and final dose level of its investigational T cell therapy for high-risk COVID-19 patients.

• Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio

  5/3/2022

  Tevogen Bio, today announced new laboratory space has been secured at CIC Philadelphia to facilitate the company’s rapid expansion of its R&D, process development, and analytical capabilities to allow for further advancement of its next generation precision T cell technology programs.